Can a daily pill ease anemia in bone marrow disorders?

NCT ID NCT07738510

Not yet recruiting Disease control Sponsor: Halia Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests an experimental oral drug, ofirnoflast, in adults with lower-risk myelodysplastic syndromes (MDS) who have anemia and need regular red blood cell transfusions. The goal is to see if the drug can reduce or eliminate transfusion needs and improve blood counts. Participants will receive one of several doses of the drug daily, and the study will compare doses to find the most effective and safe one for future testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ofirnoflast (HT-6184), an oral drug taken once daily
What this could lead to: If successful, this could lead to a new oral treatment that reduces or eliminates the need for red blood cell transfusions in people with lower-risk myelodysplastic syndromes.
What could go wrong: This is an early-stage (phase 2b) trial with only 50 participants, so results may not hold up in larger studies. The drug may cause side effects or may not improve blood counts enough to make a real difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA MYELODYSPLASTIC SYNDROMES

More trials for these conditions

Other studies related to the condition(s) this trial covers.